A Novel Approach to Gene Analysis: Gene Panels and Cluster Definition to Assist Genotyping Patients with Congenital Myopathies

Marco Calderisi¹, Ilaria Ceppa¹, Denise Cassandrini², Rosanna Trovato², Giulia Bertocci², Alessandro Tonacci¹, Guja Astrea², Raffaele Conte¹ and Filippo M. Santorelli²

¹Kode Solutions, Pisa, Italy
²IRCCS Fondazione Stella Maris, Pisa, Italy
³IFC-CNR, Pisa, Italy

Keywords: Congenital Myopathies, Muscular Dystrophies, Gene Sequencing, Non Metric Multidimensional Scaling, Clustering, High Throughput Data Analysis.

Abstract: The boundaries between congenital myopathies and muscular dystrophies and other neuromuscular disorders are becoming blurred because of the significant overlap in disease genes, clinical presentations, and histopathological features. Using a MotorPlex7.0 gene panel in massive sequencing, we define disease causative mutations in 76% of our sample. We then analysed the extent of gene information in the data using non metric multidimensional scaling (nMDS), a well-known algorithm for multivariate analysis, and clustering techniques. To perform this analysis, we developed a software that allows for an interactive exploration of the variants dataset and of the results of the nMDS model. Using these techniques, we were able to quickly study a dataset consisting of thousands of variants, identifying groupings of patients based on the presence or absence of specific sets of mutations.

1 INTRODUCTION

The term congenital myopathy refers to a group of clinically, genetically and histologically heterogeneous diseases that mainly affect skeletal muscle (Cassandrini et al., 2017). The presence of specific histopathological alterations on muscle biopsy distinguishes these conditions from other neuromuscular disorders. Congenital myopathies (CM) are caused by genetic defects in structural proteins of muscle and are classified on the basis of muscle biopsy findings (North KN et al., 2014). Although the nomenclature of CM is under constant review as more genes are identified — and the lists of associated phenotypes and histological expressions are growing at a rapid speed—, current classifications continue to rely mainly on the features seen on muscle biopsy (Cassandrini et al., 2017).

Congenital muscular dystrophies (CMD) are a group of genetically and clinically heterogeneous hereditary muscle diseases characterized by early-onset hypotonia and muscle weakness associated with dystrophic change on muscle pathology. The current classification of CMD consists of three major categories: Ullrich type CMD (collagen VI-related dystrophy), merosin-deficient CMD (LAMA2-related dystrophy) and CMD with glycosylation defect in alpha-dystroglycan (alpha-dystroglycanopathy); as well as other minor subgroups, such as LMNA-related CMD (L-CMD), megacnial type CMD, CMD with integrin alpha-7 defect, and CMD without genetic diagnosis (Bonnemann CG et al., 2014). These disorders are phenotypically diverse and genetically heterogeneous.

The boundaries between CMDs, CM, and other myopathies or limb girdle muscular dystrophies are blurred, with a significant overlap in disease genes, clinical presentations, and histopathological features. (O’Grady GL et al., 2016). Therefore, a correct diagnostic approach requires the integration of data from clinical evaluations (including a detailed family history), muscle biopsy (including histological, immunohistochemical and electron microscopy examinations) and muscular imaging at MRI and their combination might drive correct selection of the gene (or group of genes) more likely to cause the specific defect. Nonetheless, the extremely high level of genetic heterogeneity advice against a gene-after-gene strategy, while high-

Calderisi, M., Ceppa, I., Cassandrini, D., Trovato, R., Bertocci, G., Tonacci, A., Astrea, G., Conte, R. and Santorelli, F.
A Novel Approach to Gene Analysis: Gene Panels and Cluster Definition to Assist Genotyping Patients with Congenital Myopathies.
DOI: 10.5220/0007396003450352
In Proceedings of the 12th International Joint Conference on Biomedical Engineering Systems and Technologies (BIOSTEC 2019), pages 345-352
Copyright © 2019 by SCITEPRESS – Science and Technology Publications, Lda. All rights reserved
throughput strategies are recommended. Indeed, the combination of large genomic dataset, obtained by massive analysis of multiple genes with methods of next-generation sequencing (NGS), with clinical and morphological findings and MRI results has increased our chances to reach a precise molecular definition in CMD and CM (Savarese et al., 2016).

The application of NGS platforms generates an unprecedented amount of data, and this makes management, storage and, above all, analysis of the data a real challenge (Pop et al., 2008). This amount of data is such that an interconnected system (pipeline data) with very high operational capacity is required to allow its management and processing (Li et al., 2008). Moreover, targeted NGS platforms offer sufficient depth of “coverage”, molecular definition of causative variants but also a plethora of variants that are not clearly pathogenic per se but may have a modifying effect on the phenotype. Whilst several public and commercial tools are available to prioritize rare gene variants emerging in NGS studies of CMD and CM (Savarese et al., 2016; Astrea et al., 2018) and attribute causality to a specific clinical condition, how the myriad of additional less rare or frequent gene mutations contribute to a specific disorder remain largely unexplored.

In this manuscript, we designed a novel targeted gene panel (MotorPlex7.0) able to analyze massively over 200 genes in a subset of CM and CMD patients and elaborate the resulting set of data using non-metric multidimensional scaling (nMDS), a multivariate data mining algorithm that uses the information about the specific variants found in each patient to (i) compare CM and CMD groups of patients; (ii) identify groupings of patients; (iii) identify if specific genes or variants can cluster and be associated with clinical manifestations.

2 METHODS

We genotyped a sample of 159 patients (71 men and 56 women), with a clinical and morphological diagnosis of CM (127) and CMD (32) (see Figure 1 for details) using MotorPlex7.0 (Savarese et al., 206), a validated targeted gene panel containing 241 muscular genes (for a total of 1.287 Mbp of DNA) designed with the SureSelect technology (Agilent, Santa Clara, CA). Among the CM patients, clinical criteria fully met a definition of “congenital weakness and slow muscle disease progression” (North KN et al., 2014) in 72 cases whereas 54 patients had less specific clinical features overlapping other neuromuscular conditions or not sufficient data to define a CM disorder (“not specific myopathies”).

Aligning, call, and interpretation for the analysis of the data, were performed using the following softwares: SureCall (Agilent) for the assembly and alignment phase, and Ingenuity Variant analysis (QIAGEN, Hilden, Germany) and wANNOVAR (wannovar.wglab.org) for the variant calls phase and interpretation. The following criteria had to be met to reach a judgment of sequence accuracy: a quality score greater than 30 and a coverage of at least 80 reads. Freely available softwares (PolyPhen 2, http://genetics.bwh.harvard.edu/pph2/, and SIFT, http://sift.jcvi.org/) were used to predict the pathogenic effect of gene mutations. The MAF (minor allele frequency) was calculated referring to allele frequencies in several open-access population-based gene variant polymorphic databases (gnomad.broadinstitute.org, exac.broadinstitute.org/, www.ncbi.nlm.nih.gov/projects/SNP; www.internationalgenome.org/1000-genomes-browsers/) and selecting as rare variants those with an allele frequency of 0.1% (in an autosomal recessive or an X-linked model of inheritance) and 0.01% (in an autosomal dominant model of transmission.

The patients were divided into three subgroups on the basis of the certainty of their molecular diagnosis. The group with a “definite diagnosis” contains patients with published pathogenic mutations and presenting a clinical phenotype compatible with the mutation identified. The group with a “probable diagnosis” includes patients having rare mutations considered to be pathogenic based on in silico bioinformatic tools and showing clinical manifestations matching a phenotype that has already been linked to mutations in that specific gene. Cases not matching the above criteria were defined as “no diagnosis established”.

Figure 1: Distribution of patients based on clinical diagnosis.
To understand if the plethora of common variants could address specific phenotypes and assist in clustering specific gene/clinical phenotype correlations, we analyzed the variants dataset using the well-established multivariate algorithm nMDS. The aim of nMDS (Cox et al., 2001, Coxon et al., 1982) is to collapse information from more than one dimension into a smallest number of dimensions, so that they can easily be visualized and interpreted. It is a way of visualizing the level of similarity of individual cases of a dataset. Unlike other ordination techniques that primarily rely on Euclidean distances, nMDS uses rank orders, and thus is an extremely flexible technique that can accommodate a variety of different kinds of data.

nMDS works analyzing the relationship between the dissimilarities in the item-item matrix and the distances between items, and the location of each item in the designated low-dimensional space. In order to do this a cost function called “Stress”, which account of the difference between the distances in the original space and in the reduced one, is minimized. Different distances could be used with this algorithm, depending on the type of data analyzed. The genomic dataset for this study consisted of binary data, representing the presence or absence of a specific variant in each patient. We used the Jaccard distance measure as a metric for this analysis, since it is a well spread metric for measuring dissimilarity between data sets based on their shared and non-shared members (Tan et al. (2005)).

To further explore the results of the nMDS analysis we then applied a clustering algorithm on the data projection. We used k-means (J. B. MacQueen (1967)), an unsupervised learning method for clustering, that aims at classifying a given data set through a certain number of clusters (assume k clusters) fixed a priori. The main idea of the algorithm is to define k centroids, one for each cluster, and to take each point belonging to a given data set and associate it to the nearest centroid. The algorithm works iteratively to assign each data point to one of k groups based on the features that are provided. The k centroids change their location step by step until no more changes are done. The data analysis was performed using the statistical software R and the package vegan (Jari Oksanen et al. 2018). To facilitate data analysis and exploration, a web application that allows for an interactive exploration of the data from the Ingenuity software, guided by the nMDS model, has been developed.

3 RESULTS

Of the 159 patients analyzed, 66 cases (41%) received a definitive molecular diagnosis with MotorPlex7.0. A total of 122 patients (66 with a “definitive diagnosis” and 66 with a “probable diagnosis”) were identified. In details, 58 CM (33 men and 25 women, mean age at examination 38 years, mean disease duration 19 years) and 8 CMD patients (2 boys and 6 girls, mean age at examination 7 years, mean disease duration 5 years) had a full molecular definition (see Figure 2). CM patients who received a definitive diagnosis harboured mutation mostly in RYR1 (16%) and in TTN (17%, Figure 3). About half of the CMD patients who received a definitive diagnosis harboured mutation in LAMA2. We observed that there were no significant differences in diagnostic accuracy between the CM cases and those termed “not specific myopathy” (Figure 4). Overall, there were 27 “no diagnosis established” patients (18 CM and 9 CMD) implying a diagnostic yield of 76%, a value that is in keeping with the diagnostic rate observed by other groups using similar size NGS panels (see Nigro and Savarese 2016 for a review).

![Figure 2: Distribution of patients based on the result of the genetic investigation.](image-url)
Figure 3: Distribution of mutated genes in patients diagnosed with congenital myopathy.

Figure 4: Differences in diagnostic accuracy between the CM cases and those termed “not specific myopathy”.

3.1 nMDS Analysis Software

The first part of this analysis was performed using a web application developed for this purpose. Using the application, we were able to explore the dataset generated from the Ingenuity software in an intuitive, interactive and fast manner, guided by the multivariate nMDS model. The app was developed using R (R Core Team (2018)) and the package shiny (Chang et al. 2018).

A menu allows for the upload of a dataset and the application of a series of filters. It is possible to upload more than one dataset file at the same time: the app will join these files together to create a single set of data for the analysis.

After uploading the dataset, three filters are available. The first one is a sample selection filter. By means of this filter the user can choose which samples wants to exclude from the analysis. The second filter is a depth filter. Through this filter the user can choose a threshold for the read’s depth. It allow to dynamically change the value of depth at which a read should be considered reliable. Finally, the app provides a variant filter, based on the number of samples a variant is present in. The filter allows for the specification of a lower filter (only keep variants that are present in almost n samples) and an upper filter (only keep variants that are present in at most m samples). This filter enables the elimination of variants that are too rare or too common, that do not add useful information for the nMDS analysis.

The main panel of the application shows two charts. The one on the left is the nMDS representation of the samples in the new reduced dimensional space, useful to investigate if the ordering algorithm discovers some kind of grouping in the data. The plot on the right represents the projection onto the nMDS coordinate space of the variants (figure 5). By comparing these two graphs it is possible to link a possible grouping of the samples to specific set of variants: variants that fall on the
right side of the chart will be more common in patients that also falls in that part of the chart, and vice versa. Also, variants that are located in the centre of the nMDS chart are very common in the analyzed dataset, and so are not very informative for the analysis. This is the way the software also provides the user with a filter to remove those very common variants from the dataset and recompute immediately the nMDS model.

By clicking on a sample in the nMDS score chart, the app shows the variants that were found in that specific patient, by highlighting them inside the variants chart (figure 6). Moreover, by clicking on a variant, the app shows which samples had it by highlighting them in the score chart.

Furthermore, it is possible to explore the presence of mutations of a specific gene in the dataset: after the selection of a gene (or a set of genes) of interest, the application shows which samples had a variation of that gene and how these variations were distributed in the nMDS coordinate space.

3.2 Multivariate Analysis Results

A first analysis was performed on 96 CM and 31 CMD patients, to evaluate if the model could be able to distinguish between the two clinical conditions. However, this analysis was heavily influenced by the fact that the two datasets presented a very different number of variants. The CM panel consists in fact of about 20000 variants, whereas the CMD one contains about 400 variants. Since the nMDS algorithm uses the presence or absence of variants in a sample to determine the projection of those in the new space of coordinates, this difference between the two panels was the only information that the algorithm was able to find in the data (not shown).

We then analyzed the two datasets using only the 222 variants that were present at least once in both panels. Figure 8 shows the stress plot of the model computed using only those variants. The stress plot is a Shepard plot where ordination distances are plotted against the original sample’s dissimilarities, and the fit is shown as a monotone step line. The figure also shows two correlation like statistics of goodness of fit. The correlation based on stress (non metric fit) is $R^2 = 1 - S^2$, where $S$ is the final stress value of the model. The fit-based $R^2$ is the correlation between the fitted values and ordination distances (linear fit).

Figure 8: Stress plot of the nMDS model applied to the common variants of CM and CMD datasets.
The model highlights a grouping of the samples in two clusters (cluster 1 and cluster 2 in Figure 9). Although we could observe a trend to more represented CM in cluster 1 and CMD in cluster 2 (e.g., 36% versus 21% of total cluster), this subgrouping could not be related satisfactorily to the different clinical conditions. The grouping also appeared not correlated to the accuracy of diagnosis or phenotype. To determine the most characterizing variants of each cluster, we considered the variants that were found in more than 50% of the samples of only one of the two clusters. We found that a subset of variants was very common in cluster 2 and almost absent from cluster 1. These variants were all mutations of the PLEC gene (Figure 10), that was found to be the gene that better explained the clusterization of the samples in the two groups.

To further investigate the capabilities of the model, we performed an nMDS analysis on the dataset consisting of the CM patients only. A first model (with a non-metric fit, $R^2 = 0.968$ and a linear fit, $R^2 = 0.728$; not shown) did not highlight any particular clustering of the data. However, by looking at the variants chart we noticed that a big chunk of those were located in the centre of the plot, meaning that they were very common in the majority of the samples in the dataset. We then decided to repeat the analysis removing the variants that were in the circle of radius 0.2 of the nMDS space (Figure 3A) and this produced a better fit and stress model (Figure 11). With this second analysis, a defined grouping of the samples emerged.

We applied a clustering algorithm to the model’s projection of the samples, in order to determine what groups emerged from the nMDS. We used the k-means clustering algorithm, and we determined the value of the parameter k (number of clusters) by plotting the total within-cluster sum of squares for different values of this parameter (knee plot). We decided to set $k=3$; the results of the clustering algorithm are shown in Figure 12. Again, the groups highlighted by the model did not appear to be related to neither the diagnosis nor the phenotype. We selected the variants that were found to be present in more than 60% of the samples of only one of the three clusters: this way we were able to identify the characterizing variants of each one of the clusters, and then to determine the corresponding genes. We found that cluster 2 had a higher occurrence of variants in the RYR1 gene compared to the other two clusters, whereas the samples in cluster 3 had a higher occurrence of variants of the TTN gene (figure 13).
4 DISCUSSION

This study illustrates the use of a large gene panel (MotorPlex7.0) to investigate the molecular determinants in a group of patients with CM or CMD. We also analyzed the genomic data to investigate how patients and mutations can be clustered on the basis of their phenotype or characterizing gene variant.

Our results indicate the following considerations. First, we examined a relatively large dataset and discovered mutations of diagnostic significance in over 75% of the patients illustrating both the accuracy of clinical and morphological criteria used to diagnose patients and the diagnostic power of our panel. Second, we studied this dataset using multivariate data analysis techniques able to define clusters between different clinical phenotypes and list of gene variants (rare and common). The novel module could identify the characterizing PLEC gene, the gene that encodes plectin-1, one of the largest polypeptides known representing a major component of intermediate filament believed to provide mechanical strength to cells and tissues by acting as a cross-linking element of the cytoskeleton. The identification of PLEC mutations especially in cluster 1 where CM more than CMD cases appear to be present is well in line with the more “structural” effects that genes associated with CM disrupt in skeletal muscle. Third, and finally, our novel approach opens to the possibility to define a new dimension when mutations and clinical manifestations are correlated. Hopefully this could contribute new molecular targets of gene modifiers in the heterogeneous muscular dystrophies and myopathies.

ACKNOWLEDGEMENTS

This work was partially funded by Regione Toscana FAS SALUTE 2014 (to FMS and MC, CUP 4042.16092014.066000060) and Telethon Foundation grants GUP13004 to GA).

REFERENCES


Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 2008; 18:1851-8

